Designing photosensitizers for photodynamic therapy: Strategies, challenges and promising developments

Future Medicinal Chemistry

Volumn 1, Issue 4, 2009, Pages 667-691

  Garland, Martin J ^a   Cassidy, Corona M ^a   Woolfson, David ^a   Donnelly, Ryan F ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; BACTERIOCHLORIN; BENZOPORPHYRIN DERIVATIVE; CHLORIN; METAL ION; NANOPARTICLE; PHENOTHIAZINIUM; PHOTOSENSITIZING AGENT; PHTHALOCYANINE; PORPHYCENE; PORPHYRIN; PURPURIN; TEXAPHYRIN; UNCLASSIFIED DRUG;

DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULATION; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; LIGHT ABSORPTION; LIPOPHILICITY; MEDICAL RESEARCH; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW;

AMINOLEVULINIC ACID; ANTI-INFECTIVE AGENTS; DIHEMATOPORPHYRIN ETHER; DRUG DESIGN; GRAM-NEGATIVE BACTERIAL INFECTIONS; GRAM-POSITIVE BACTERIA; HUMANS; INDOLES; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS;

EID: 77953464531     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.09.55     Document Type: Review

References (160)

1. Wainwright M. Photodynamic antimicrobial chemotherapy (PACT). J. Antimicrob. Chemother. 42, 13-28 (1998).
2. Donnelly RF, McCarron PA, Tunney MM. Antifungal photodynamic therapy. Microbiol. Res. 163, 1-12 (2008).
3. Konan YN, Gurny R, Allemann E. State of the art in the delivery of photosensitizers for photodynamic therapy. J. Photochem. Photobiol. B Biol. 66, 89-106 (2002).
4. Isaacs NS. Physical Organic Chemistry. Longman Scientific and Technical, Essex, UK 779-781 (1992).
5. Kalyanasundaram K. Photochemistry of Polypyridine and Porphyrin Complexes. Academic Press, London, UK, 403-421 (1992).
6. Henderson BW, Dougherty TJ. How does photodynamic therapy work? Photochem. Photobiol. 55, 145-157 (1992).
7. Kalka K, Merk H, Mukhtar H. Photodynamic therapy in dermatology. J. Am. Acad. Dermatol. 42, 389-413 (2000).
8. Oschner M. Photophysical and photobiological processes in the photodynamic therapy of tumours. J. Photochem. Photobiol. B Biol. 39, 1-18 (1997).
9. Gannon MJ, Brown SB. Photodynamic therapy and its applications in gynaecology. Br. J. Obstet. Gynecol. 106, 1246-1254 (1999).
10. De Rosa FS, Bentley MVLB. Photodynamic therapy of skin cancers: sensitizers, clinical studies and future directives. Pharm. Res. 17, 1447-1455 (2000).
11. Dougherty TJ, Gomer CJ, Henderson BW et al. Photodynamic therapy. J. Nat. Cancer Instit. 90, 889-905 (1998).
12. Pottier R, Kennedy JC. New trends in photobiology (invited review) the possible role of ionic species in selective biodistribution of photochemotherapeutic agents toward neoplastic tissue. J. Photochem. Photobiol. B Biol. 8, 1-16 (1990).
13. Kennedy JC, Pottier RH, Pross DC. Photodynamic therapy with endogenous protoporphyrin IX: basic principals and present clinical experience. J. Photochem. Photobiol. B Biol. 6, 143-148 (1990).
14. Fernandez JM, Bilgin MD, Grossweiner LI. singlet oxygen generation by photodynamic agents. J. Photochem. Photobiol. B Biol. 37, 131-140 (1997).
15. Fuchs J, Thiele J. The role of oxygen in cutaneous photodynamic therapy. Free Radical Biol. Med. 24, 835-847 (1998).
16. Morton CA, Brown SB, Collins S et al. Guidelines for topical photodynamic therapy: a report of a workshop of the british photodermatology group. Br. J. Dermatol. 146, 552-567 (2002).
17. Moan J. On the diffusion length of singlet oxygen in cells and tissues. J. Photochem. Photobiol. B Biol. 6, 343-347 (1990).
18. Moor CE. Signalling pathways in cell death and survival after photodynamic therapy. Photochem. Photobiol. B Biol. 57, 1-13 (2000).
19. Roberts DJH, Cairnduff F, Driver I, Dixon B, Brown SB. Tumour vascular shutdown following photodynamic therapy based on polyhaematoporphyrin or 5-aminolevulinic acid. Int. J. Oncol. 5, 763-768 (1994).
20. Martin J, Mehta DK, Jordan B et al. British National Formulary (53rd Edition). BMJ Publishing Group Ltd, London, UK, 458 (2007).
21. Griffiths MA, Wren BW, Wilson M. Killing of methicillin-resistant Staphylococcus aureus in vitro using aluminium disulphonated phthalocyanine, a light-activated antimicrobial agent. J. Antimicrob. Chemother. 40, 873-876 (1997).
22. Donnelly RF, McCarron PA, Cassidy CM, Elborn JS, Tunney MM. Delivery of photosensitisers and light through mucus: investigations into the potential use of photodynamic therapy for treatment of Pseudomonas aeruginosa cystic fibrosis pulmonary infection. J. Control. Release 117, 217-226 (2007).
23. Sharma M, Visai L, Bragheri F, Christiani I, Gupta PK, Speziale P. Toluidine bluemediated photodynamic effects on staphylococcal biofilms. Antimicrob. Agents Chemother. 52, 299-305 (2008).
24. Tang HM, Hamblin MR, Yow CM. A comparative in vitro photoinactivation study of clinical isolates of multidrug-resistant pathogens. J. Infect. Chemother. 13, 87-91 (2007).
25. Smetana Z, Ben-Hur E, Mendelson E, Salzberg S, Wagner P, Malik Z. Herpes simplex virus proteins are damaged following photodynamic inactivation with phthalocyanines. J. Photochem. Photobiol. B Biol. 44, 77-83 (1998).
26. Smetana Z, Mendelson E, Manor J et al. Photodynamic inactivation of herpes viruses with phthalocyanine derivatives. J. Photochem. Photobiol. B Biol. 22, 37-43 (1994).
27. Schagen FH, Moor AC, Cheong SC et al. Photodynamic treatment of adenoviral vectors with visible light: an easy and convenient method for viral inactivation. Gene Ther. 6, 873-881 (1999).
28. Roamgnoli C, Mares D, Sacchetti G, Bruni A. The photodynamic effect of 5-(4-hydroxy- 1-butinyl)-2,2-bithienyl on dermatophytes. Mycol. Res. 12, 1519-1524 (1998).
29. Brancaleon L, Moseley H. Laser and non-laser light sources for photodynamic therapy. Lasers. Med. Sci. 17, 173-186 (2002).
30. Ceburkov O, Gollnick H. Photodynamic therapy in dermatology. Eur. J. Dermatol. 10, 568-576 (2000).
31. Oschner M. Light scattering of human skin: a comparison between zinc (II) phthalocyanine and photofrin II. Photochem. Photobiol. B Biol. 21, 3-9 (1996).
32. Copeland LJ. Textbook of Gynecology. WB Saunders, PA, USA, 1252-1253 (2000).
33. Soler AM, Warloe T, Berner A, Giercksky KE. A follow-up study of recurrence and cosmesis in completely responding superficial and nodular basal cell carcinomas treated with methyl 5-aminolevulinate-based photodynamic therapy alone with prior curettage. Br. J. Dermatol. 145, 467-471 (2001).
34. Hisazumi H, Ueki O, Kumaki O, Naito K, Misaki T. Photodynamic therapy of superficial tumors and carcinoma in situ of the bladder. Gan. No Rinsho. 6, 697-703 (1985).
35. MacCormack MA. Photodynamic therapy. Adv. Dermatol. 22, 219-258 (2006)
36. Pushpan SK, Venkatraman S, Anand VG et al. Porphyrins in photodynamic therapy - a search for ideal photosensitizers. Curr. Med. Chem. Anticancer Agents. 2, 187-207 (2002).
37. Berg K, Selbo PK, Weyergang A, Dietze A et al. Porphyrin-related photosensitisers for cancer imaging and therapeutic applications. J. Microsc. 218, 133-147 (2005).
38. Palumbo G. Photodynamic therapy and cancer: a brief sightseeing tour. Expert Opin. Drug Deliv. 4, 131-148 (2007).
39. Calzavara-Pinton PG, Venturini M, Sala R. Photodynamic therapy: update 2006. Part 1: photochemistry and photobiology. J. Eur. Acad. Dermatol. Venereol. 21, 293-302 (2007).
40. Chen B, Pogue BW, Hoopes PJ, Hasan T. Vascular and cellular targeting for photodynamic therapy. Crit. Rev. Eukaryot. Gene Expr. 16, 279-305 (2006).
41. Jori G, Beltramini M, Reddi E et al. Evidence for a major role of plasma lipoproteins as hematoporphyrin carriers in vivo. Cancer Lett. 24, 291-297 (1984).
42. Juzeniene A, Juzenas P, Ma LW, Iani V, Moan J. Topical application of 5-aminolaevulinic acid, methyl 5-aminolaevulinate and hexyl 5-aminolaevulinate on normal human skin. Br. J. Dermatol. 155, 791-799 (2006).
43. Moan J, Sommer S. Uptake of the components of hematoporphyrin derivative by cells and tumours. Cancer Lett. 21, 167-174 (1983).
44. Fuchs C, Riesenberg R, Siegert J, Baumgartner R. pH-dependent formation of 5-aminolevulinic acid-induced protoporphyrin IX in fibrosarcoma cells. J. Photochem. Photobiol. B. Biol. 40, 49-54 (1997)
45. Wike-Hooley JL, Haveman J, Reinhold HS. The relevance of tumour pH to the treatment of malignant disease. Radiother. Oncol. 2, 343-366 (1984)
46. Peng Q, Nesland JM. Effects of photodynamic therapy on tumor stroma. Ultrastruct. Pathol. 28, 333-340 (2004)
47. Hopper C. Photodynamic therapy: a clinical reality in the treatment of cancer. Lancet Oncol. 1, 212-219 (2000).
48. Soukos NS, Wilson M, Burns T, Speight PM. Photodynamic effects of toluidine blue on human oral keratinocytes and fibroblasts and Streptococcus sanguis evaluated in vitro. Lasers Surg. Med. 18, 253-259 (1996).
49. Zeina B, Greenman J, Corry D, Purcell WM. Antimicrobial photodynamic therapy: assessment of genotoxic effects on keratinocytes in vitro. Br. J. Dermatol. 148, 229-232 (2003).
50. Menezes PFC, Imasato H, Ferreira J, Bagnato HS, Sibata CH, Perussi JR. Aggregation susceptibility on phototransformation of hematoporphyrin derivatives. Laser Phys. Lett. 5(3) 227-235 (2008).
51. Zimcik P, Miletin M, Kopecky K et al. Influence of aggregation on interaction of lipophilic, water-insoluble azapthalocyanines with DOPC vesicles. J. Photochem. Photobiol. 83, 1497-1504 (2007).
52. Govil SK. Transdermal drug delivery systems. In: Drug Delivery Devices. Tyle P (Ed.). Marcel Dekker, NY, USA (1988).
53. Jin ZH, Miyoshi N, Ishiguro K et al. Photodynamic therapy based on combined use of 5-aminolevulinic acid with a pheophoride - a derivative for murine tumors. In vivo 14, 529-534 (2000).
54. Wong TW, Aizawa K, Sheyhedin I, Wushur C, Kato H. Pilot study of topical delivery of mono-L-aspartyl chlorin e6 (NPe6): implication of topical NPe6-photodynamic therapy. J. Pharmacol. Sci. 93, 136-142 (2003).
55. Smith GT, Yang T, Baldock GA, Brodie RR, Hill HM, Morris GR. The impact of stability and solubility of photodynamic therapies on method development. Chromatographia. 55, S171-S175 (2002).
56. Kano K, Nakajima T, Takei M, Hashimoto S. Self aggregation of cationic porphyrin in water. Bull. Chem. Soc. Jpn 60, 1281-1287 (1987).
57. Dhami S, Phillips D. Comparison of the photophysics of an aggregating and non-aggregating aluminium phthalocyanine system incorporated into unilamellar vesicles. J. Photochem. Photobiol. A Chem. 100, 77-84 (1996).
58. Bonnett R, Djelal BD, Nguyen A. Physical and chemical studies related to the development of m-THPC (FOSCAN) for the photodynamic therapy (PDT) of tumours. J. Porphyrins Phthalocyanines 5, 652-661 (2001).
59. Cassidy C, Tunney MM, McCarron PA, Donnelly RF. Drug delivery strategies for photodynamic antimicrobial chemotherapy: from benchtop to clinical practice. J. Photochem. Photobiol. B Biol. 95(2), 71-80 (2009).
60. You Y, Gibson SL, Hilf R et al. Water soluble core-modified porphyrins 3. Synthesis, photophysical properties, and in vitro studies of photosensitization, uptake, and localization with carboxylic acid-substituted derivatives. J. Med. Chem. 46(17) 3734-3747 (2003).
61. A history of photodynamic therapy. Daniell MD, Hill JS. Austral. New Zeal. J. Surg. 61, 340-348 (1991).
62. Moan J, Peng Q. An outline of the hundredyear history of PDT. Anticancer Res. 23, 3591-3600 (2003).
63. Donnelly RF, McCarron PA, Woolfson AD. Drug delivery of aminolevulinic acid from topical formulations intended for photodynamic therapy. Photochem. Photobiol. 81, 750-767 (2005).
64. Donnelly RF, McCarron PA, Morrow DI, Sibani SA, Woolfson AD. Photosensitiser delivery for photodynamic therapy. Part 1: topical carrier platforms. Expert Opin. Drug Deliv. 7, 757-766 (2008).
65. Kennedy JC, Marcus SL, Pottier RH. Photodynamic therapy (PDT) and photodiagnosis (PD) using endogenous photosensitization induced by 5-aminolevulinic acid (ALA): mechanisms and clinical results. J. Clin. Laser Med. Surg. 14, 289-304 (1996).
66. Meijnders PJN, Star WM, De Bruijn RS et al. Lasers Med. Sci. 11, 123-131 (1996).
67. Peng Q, Warloe T, Berg K et al. 5-aminolevulinic acid-based photodynamic therapy. Clinical research and future challenges. Cancer 79, 2282-2308 (1997).
68. Berg K, Anholt H, Bech O, Moan J. Apoptosis and necrosis induced with light and 5-aminolaevulinic acid-derived protoporphyrin IX. Br. J. Cancer 74, 688-697 (1996).
69. Bottomley S, Muller-Eberhard U. Pathophysiology of heme synthesis. Sem. Heme Synth. 25, 282-302 (1988).
70. Moan J, Berg K, Gadmar O, Iani V, Ma LW, Juzenas P. The temperature dependence of protoporphyrin IX production in cells and tissues. Photochem. Photobiol. 70, 669-673 (1999).
71. Gibson SL, Havens JJ, Metz L, Hilf R. Is ?-aminolevulinic acid dehydratase rate limiting in heme biosynthesis following exposure of cells to δ-aminolevulinic acid? Photochem. Photobiol. 73, 312-317 (2001).
72. Krieg RC, Fickweiler S, Appel S, Wolfbeis OS, Knuechel R. Cell-type specific protoporphyrin IX metabolism in human bladder cancer in vitro. Photochem. Photobiol. 72, 226-233 (2000).
73. Krieg RC, Messmann H, Rauch J, Seeger S, Knuechel R. Metabolic characterization of tumor cell-specific protoporphyrin IX accumulation after exposure to 5-aminolevulinic acid in human colonic cells. Photochem. Photobiol. 76, 518-525 (2002).
74. Schneegurt MAJ. δaminolevulinic acid biosynthesis in Ustilago maydis. Basic Microbiol. 45, 155-159 (2005).
75. Kikuchi G, Kumar A, Talmage P, Shemin DJ. Biol. Chem. 233, 1214-1219 (1958).
76. Beale SI, Castelfranco PA. The biosynthesis of δ-aminolevulinic acid in higher plants. Plant Physiol. 53, 297-303 (1974).
77. Fukuda H, Casas A, Batlle A. Aminolevulinic acid: from its unique biological function to its star role in photodynamic therapy. Int. J. Biochem. Cell Biol. 37, 272-276 (2005).
78. Kloek J, Beijersbergen Van Henegouwen MJ. Prodrugs of 5-aminolevulinic acid for photodynamic therapy. Photochem. Photobiol. 64, 994-1000 (1996).
79. Berge SM, Bighley LD, Monkhouse DC. Pharmaceutical salts. J. Pharm. Sci. 66, 1-19 (1977).
80. Uehlinger P, Zellweger M, Wagnieres G, Juillerat-Jeanneret L, Van den Bergh H, Lange NJ. 5-aminolevulinic acid and its derivatives: physical chemical properties and protoporphyrin IX formation in cultured cells. Photochem. Photobiol. B Biol. 54, 72-80 (2000).
81. Smal MA, Dong Z, Cheung HT et al. Activation and cytotoxicity of 2-α-aminoacyl prodrugs of methotrexate. Biochem. Pharmacol. 49, 567-574 (1995).
82. Ashmun RA, Look AT. Metalloprotease activity of CD13/aminopeptidase N on the surface of human myeloid cells. Blood 75, 462-469 (1990).
83. Saiki I, Fujii H, Yoneda J et al. Antimetastatic activity of polymeric RGDT peptides conjugated with poly(ethylene glycol). Int. J. Cancer 54, 137-143 (1993).
84. Berger Y, Greppi A, Siri O, Neier R, Juillerat-Jeanneret LJ. Ethylene glycol and amino acid derivatives of 5-aminolevulinic acid as new photosensitizing precursors of protoporphyrin IX in cells. Med. Chem. 43, 4738-4746 (2000).
85. Berger Y, Ingrassia L, Neier R, Juillerat-Jeanneret L. Evaluation of dipeptidederivatives of 5-aminolevulinic acid as precursors for photosensitizers in photodynamic therapy. Bioorg. Med. Chem. 11, 1341-1351 (2003).
86. Battah SH, Chee CE, Nakanishi H, Gerscher S, MacRobert AJ, Edwards C. Synthesis and biological studies of 5-aminolevulinic acid-containing dendrimers for photodynamic therapy. Bioconjug. Chem. 12, 980-988 (2001).
87. Gravier J, Schneider R, Frochot C et al. Improvement of meta-tetra (hydroxyphenyl) chlorine-like photosensitiser selectivity with folate based targeted delivery: synthesis and in vivo delivery studies. J. Med Chem. 51, 3867-3877 (2008).
88. Josefsen LB, Boyle RW. Photodynamic therapy and the development of metal-based photosensitisers. Br. J. Pharmacol. 154(1), 1-3 (2008).
89. Banfi S, Caruso E, Capriol S et al. Photodynamic effect of porphyrin and chlorin photosensitisers in human colon adenocarcinoma cells. Bioorg. Med. Chem. 12, 4853-4860 (2004)
90. Kral V, Kralova J, Kaplanek R, Briza T, Martasek P. Quo vadis porphyrin chemistry? Physiol. Res. 55(Suppl. 2), S3-S26 (2006).
91. Wall MH Jr, Basu P, Buranda T et al. Photoinduced electron transfer in covalently linked oxomolybdenum(V) porphyrin systems. Inorg. Chem. 36, 5676-5677 (1997).
92. Samaroo D, Vinodu M, Chen X, Drain CM. Meso-tetra(pentafluorophenyl) porphyrin is an efficient platform for combinatorial synthesis, and the selection of new photodynamic therapeutics using a cancer cell line. J. Comb. Chem. 9, 998-1011 (2007).
93. Sibrian-Vazquez M, Jensen TJ, Graca M, Vicente H. Synthesis and cellular studies of PEG-functionalized mesotetraphenylporphyrins. J. Photochem. Photobiol. B 86, 9-21 (2007).
94. Kralova J, Briza T, Moserova I et al. Glycol porphyrin derivatives as potent photodynamic inducers of apoptosis in tumor cells. J. Med. Chem. 51, 5964-5973 (2008).
95. Zalipsky S, Puntambekar B, Boulikas P, Engbers CM, Woodle MC. Peptide attachment to extremities of liposomal surface grafted PEG chains: preparation of the long circulating form of laminin pentapeptide, YIGSR. Bioconjug. Chem. 6, 705-708 (1995).
96. Hamblin MR, Zahra T, Contag CH, McManus AT, Hasan T. Optical monitoring and treatment of potentially lethal wound infections in vivo. J. Infect. Dis. 187, 1717-1725 (2003).
97. Sol V, Chaleix V, Champavier Y, Granet R, Huang Y, Krausz P. Glycosyl bis-porphyrin conjugates: synthesis and potential application in PDT. Bioorg. Med. Chem. 14, 7745-7760 (2006).
98. Obata M, Hirohara S, Sharyo K et al. Sugar-dependent photodynamic effect of glycoconjugated porphyrins: a study on photocytotoxicity, photophysical properties and binding behaviour to bovine serum albumin (BSA). Biochimica Biophysica Acta. 1770, 1204-1211 (2007).
99. Hirohara S, Obata M, Alitomo H et al. Structure-photodynamic effect relationship of 24 glycoconjugated photosensitisers in HeLa cells. Biol. Pharm. Bull. 31, 2265-2272 (2008).
100. O'Neal WG, Roberts WP, Ghosh I, Wang H, Jacobi PA. Studies in chlorin chemistry 3: a practical synthesis of c,d-ring symmetric chlorins of potential utility in photodynamic therapy. J. Org. Chem. 71, 3472-3480 (2006).
101. Triesscheijn M, Ruevekamp M, Aalders M, Baas P, Stewart FA. Outcome of mTHPC mediated photodynamic therapy is primarily determined by the vascular response. Photochem. Photobiol. 81, 1161-1170 (2005).
102. Houle JM, Strong A. Clinical pharmacokinetics of verteporfin. J. Clinical Pharmacol. 42, 547-557 (2002).
103. La Cour M, Kiilgaard JF, Nissen MH. Age-related macular degenaration. Drugs Aging 19, 101-133 (2002).
104. Mittra RA, Singerman L. Recent advances in the management of age-related macular degeneration. Optom. Vis. Sci. 79, 218-224 (2002).
105. Koh AHC, Ang CL. Age-related macular degeneration: what's new? Ann. Acad. Med. Singap. 31, 399-404 (2002).
106. Obana A, Gohto Y. Scanning laser system for photodynamic therapy of choroidal neovascularization. Lasers Surg. Med. 30, 370-375 (2002).
107. Razum NJ, Snyder AB, Doiron DR. SnET2: clinical update. Proc. SPIE 2675, 43-46 (1996).
108. Henderson BW, Bellnier DA, Greco WR et al. An in vivo quantitative structure activity relationship for a congeneric series of pyropheophorbide derivatives as photosensitisers for photodynamic therapy. Cancer Res. 57, 4000-4007 (1997).
109. Potter WR, Henderson BW, Bellnier DA et al. Parabolic quantitative structure-activity relationships and photodynamic therapy: application of a three compartment model with clearance to the in vivo quantitative structure-activity relationships of a congeneric series of pyropheophorbide derivatives used as photosensitisers for photodynamic therapy. Photochem. Photobiol. 70, 781-788 (1999).
110. Zhang M, Zhang Z, Blessington D et al. Pyropheophorbide 2-deoxyglucosamide: a new photosensitiser targeting glucose transporters. Bioconjugate Chem. 14, 709-714 (2003).
111. Macdonald IJ, Dougherty TJ. Basic principles of photodynamic therapy. J. Porphyrins. Phthalocyanines 5, 105-129 (2001).
112. Wiehe A, Ryppa C, Senge MO. A practical synthesis of meso- monosubstituted, β-unsubstituted porphyrins. Org. Lett. 4, 3807-3809 (2002).
113. Rancan F, Wiehe A, Nobel A et al. Influence of substitution on asymmetric dihydroxychlorins with regard to intracellular uptake, subcellular localization and photosensitization of Jurkat cells. J. Photochem. Photobiol. B 78, 17-28 (2005).
114. Margaron P, Gregoire MI, Scasnar V, Ali H, Van Lier SE. Structure-photodynamic activity relationship of a series of 4-substituted zinc phthalocyanines. Photochem. Photobiol. 63, 217-223 (1996).
115. Boyle RW, Dolphin D. Structure and biodistrubition relationships of photodynamic photosensitisers. Photochem. Photobiol. 64, 469-485 (1996).
116. Ricchelli F. Photophysical properties of porphyrins in biological membranes. J. Photochem. Photobiol. B 29, 109-118 (1995).
117. Ma L, Moan J, Berg K. Evaluation of a new photosensitiser meso-tetra-hydroxyphenylchlorin, for use in photodynamic therapy: a comparison of its photobiological properties with those of two other photosensitisers. Int. J. Cancer. 57, 883-888 (1994).
118. Palma M, Cardenas-Jiron GI, Menendez- Rodriguez MI. Effect of chlorin structure on theoretical electronic absorption spectra and on the energy released by porphyrin based photosensitisers. J. Phys. Chem. A 112, 13574-13583 (2008).
119. Weersink RA, Bogaards A, Gertner M et al. Techniques for delivery and monitoring of TOOKAD (WST09)-mediated photodynamic therapy of the prostate: Clinical experience and practicalities. J. Photchem. Photobiol. B Biol. 79, 211-222 (2005).
120. Trachtenberg J, Bogaards A, Weersink RA et al. Vascular targeted photodynamic therapy with palladium bacteriopheophorbide photosensitiser for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response. J. Urol. 178, 1974-1979 (2007).
121. Gross S, Gilead A, Scherz A, Neeman M, Salomon Y. Monitoring photodynamic therapy of solid tumours online by bold contrast. Nat. Med. 9, 1327-1331 (2003).
122. Koudinova NV, Pinthus JH, Brandis A et al. Photodynamic therapy with Pdbacteriopheophorbide (TOOKAD): successful in vivo treatment of human prostatic small cell carcinoma xenografts. Int. J. Cancer 104, 782-790 (2003).
123. Gertner MR, Bogaards A, Weersink RA et al. Presented at: Society of Urologic Oncology, 4th Annual Meeting. Bethesda, MD, USA, 5-6 December 2003.
124. Ruck A, Bohmler A, Steiner R. PDT with TOOKAD studied in the chorioallantoic membrane of fertilized eggs. Photodiagnosis Photodyn. Ther. 2, 79-90 (2005).
125. Woodburn KW, Fan Q, Kessel D, Wright M, Mody TD, Hemmi G. Phototherapy of cancer and atheromatous plaques with texaphyrins. J. Clin. Las. Med. Surg. 14, 343-348 (1996).
126. Renschler MF, Yuen A, Panella TJ, Wieman TJ, Julius C, Panjehpour M. Photodynamic therapy trials with lutetium texaphyrin. Photochem. Photobiol. 65, 47S (1998).
127. Gurol I, Durmus M, Ahsen V, Nyokong T. Synthesis, photophysics and photochemical properties of substituted zinc phthalocyanines. Dalton Transactions 3782-3791 (2007).
128. Idowu M, Nyokong T. Synthesis, photophysics and photochemistry of tin(IV) phthalocyanine derivatives. J. Photochem. Photobiol. A. 199, 282-290 (2008).
129. De Filippis MP, Dei D, Fantetti L, Roncucci G. Synthesis of a new water-soluble octacationic phthalocyanine derivative for PDT. Tetrahedron Lett. 41, 9143-9147 (2000).
130. Miller JD, Baron ED, Scull H et al. Photodynamic therapy with the phthalocyanine photosensitiser Pc 4: the case experience with preclinical mechanistic and early clinical translational studies. Toxicol. Appl. Pharmacol 224, 290-299 (2007).
131. Swick A, Camouse M, Mc Cormick T et al. Successful penetration of topically applied silicon phthalocyanine photosensitiser pc 4 and new pc 4 salts into human skin. JID 122, 146 (2004).
132. Atilla D, Durmus M, Gurek AG, Ahsen V, Nyokong T. Synthesis, photophysical and photochemical properties of poly(oxyethylene)- substituted zinc phthalocyanines. Dalton Trans. 12, 1235-1243 (2007).
133. Zimcik M, Miletin M, Kostka J, Schwarz Z, Kopecky K. Synthesis and comparison of photodynamic activity of alkylheteroatom substituted azaphthalocyanines. J. Photochem. Photobiol. A 163, 21-28 (2004).
134. Durmus M, Nyokong T. Synthesis, photophysical and photochemical studies of new water-soluble indium (III) phthalocyanines. Photochem. Photobiol. Sci. 6, 659-668 (2007).
135. Vogel E, Kocher M, Schmickler H, Lex J. Porphycene - a novel porphyrin isomer. Angew. Chem. Int. Ed. Engl. 25, 257-258 (1986).
136. Rubio N, Prat F, Bou N et al. A comparison between the photophysical and photosensitising properties of tetraphenyl porphycenes and porphyrins. New. J. Chem. 29, 378-384 (2005).
137. Rubio N, Snchez-Garca D, Jimnez-Banzo A et al. Effect of Aza substitution on the photophysical and electrochemical properties of porphycenes. J. Phys. Chem. A 110, 3480-3487 (2006).
138. Hamblin MR, Hama T. Photodynamic herapy: a new antimicrobial approach to infectious disease? J. Photochem. Photobiol. 3, 436-450 (2004).
139. Jori G, Fabris C, Soncin M et al. Photodynamic therapy in the treatment of microbial infections: basic principles and perspective applications. Lasers Surg. Med. 38, 468-481 (2006).
140. Tegos GP, Hamblin MR. Phenothiazinium antimicrobial photosensitizers are substrates of bacterial multidrug resistance pumps. Antimicrob. Agents. Chemother. 50, 196-203 (2006).
141. Wainwright M, Crossley KB. Photosensitising agents - circumventing resistance and breaking down biofilms: a review. Int. Biodet. Biodeg. 53, 119-126 (2004).
142. Komerik N, Nakanishi H, MacRobert AJ, Henderson B, Speight P, Wilson M. In vivo killing of Porphyromonas gingivalis by toluidine blue-mediated photosensitization in an animal model. Antimicrob. Agents Chemother. 47, 932-940 (2003).
143. Wainwright M. Methylene blue derivatives - suitable photoantimicrobials for blood product disinfection? Int. J. Antimicrob. Agents 16, 381-394 (2000).
144. Wainwright M. Phenothiazinium photosensitisers: V. Photobactericidal activities of chromophore-methylated phenothiazinium salts. Dyes Pigments 73, 7-12 (2007).
145. Wilson M. Light-activated antimicrobial coating for the continuous disinfection of surfaces. Infect. Control Hosp. Epidemiol. 24, 782-784 (2003).
146. Phoenix DA, Sayed Z, Hussain S, Harris F, Wainwright M. The phototoxicity of phenothiazinium derivatives against Escherichia coli and Staphylococcus aureus. FEMS Immunol. Med. Microbiol. 39, 17-22 (2003).
147. Miller K, O'Neill AJ, Chopra I. Response of Escherichia coli hypermutators to selection pressure with antimicrobial agents from different classes. J. Antimicrob. Chemother. 49, 925-934 (2002).
148. Romanova NA, Brovko LY, Moore L, Pometun E, Savitsky AP, Ugarova NN, Griffiths MW. Assessment of photodynamic destruction of Escherichia coli 0157: H7 and listeria monocytogenes by using ATP bioluminescence. Appl. Environ. Microbiol. 69, 6393-6398 (2003).
149. Wong TW, Wang YY, Sheu HM, Chuang YC. Bactericidal effects of toluidine blue-mediated photodynamic action on Vibrio vulnificus. Antimicrob. Agents Chemother. 49, 895-902 (2005).
150. Anderson R, Loebel N, Hammond D, Wilson M. Treatment of periodontal disease by photodisinfection compared to scaling and root planning. J. Clin. Dent. 18, 34-38 (2007).
151. Minnock A, Vernon DI, Schofield J, Griffiths J, Parish JH, Brown ST. Photoinactivation of bacteria. Use of a cationic water-soluble zinc phthalocyanine to photoinactivate both Gram-negative and Gram-positive bacteria. J. Photochem. Photobiol. B. Biol. 32, 159-164 (1996).
152. Jori G, Brown SB. Photosensitized inactivation of microorganisms. Photochem. Photobiol. Sci. 3, 403-405 (2004).
153. Reddi E, Ceccon M, Valduga G et al. Photophysical properties and antibacterial activity of meso-substituted cationic porphyrins. Photochem. Photobiol. Sci. 5, 462-470 (2002).
154. Spesia MB, Lazzeri D, Pascual L, Rovera M, Durantini EN. Photoinactivation of Escherichia coli using porphyrin derivatives with different number of cationic charges. FEMS Immunol. Med. Microbiol. 3, 289-295 (2005).
155. Jones SG, Edwards R, Thomas DW. Inflammation and wound healing: the role of bacteria in the immuno-regulation of wound healing. Int. J. Low Extrem. Wounds 3, 201-208 (2004).
156. Gad F, Zahra T, Francis KP, Hasan T, Hamblin MR. Targeted photodynamic therapy of established soft-tissue infections in mice. Photochem. Photobiol. Sci. 3, 451-458 (2004).
157. Embleton ML, Nair SP, Heywood W, Menon DC, Cookson BD, Wilson M. Development of a novel targeting system for lethal photosensitization of antibioticresistant strains of Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 3690-3696 (2005).
158. Berthiaume F, Reiken SR, Toner M, Tompkins RG, Yarmush ML. Antibodytargeted photolysis of bacteria in vivo. Biotechnology (NY) 12, 703-706 (1994).
159. Barrow PA, Soothill JS. Bacteriophage therapy and prophylaxis: rediscovery and renewed assessment of potential. Trends Microbiol. 5, 268-271 (1997).
160. Mellish KJ, Cox RD, Vernon DI, Griffiths J, Brown SB. In vitro photodynamic activity of a series of methylene blue analogues. Photochem. Photobiol. 75, 392-397 (2002).